Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
BMJ (Clinical Research Ed.)|May 13, 2011
Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched studyMette Charlot, Erik L Grove, Peter Riis Hansen, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 17, 2017
Advocating cardiovascular precision medicine with P2Y12 receptor inhibitorsMax-Paul Winter, Erik L Grove, Raffaele De Caterina, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 19, 2020
Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathyKamilla P Bjerre, Tor S Clemmensen, Katrine Berg, et al.
Contemporary Clinical Trials Communications|September 3, 2020
Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarctionEva Prescott, John Pernow, Antti Saraste, et al.
International Journal of Cardiology|July 16, 2022
Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR studyEva Prescott, Oskar Angerås, David Erlinge, et al.
AJR. American Journal of Roentgenology|June 16, 2021
Impact of Dose Reduction Strategies on Image Quality of Coronary CTA in Real-World Clinical Practice: A Subanalysis of PROTECTION VI Registry DataThomas J Stocker, Nils Nühlen, Axel Schmermund, et al.
Clinical Cardiology|September 3, 2022
Influence of intensive lipid-lowering on CT derived fractional flow reserve in patients with stable chest pain: Rationale and design of the FLOWPROMOTE studyMartin B Mortensen, Niels-Peter Sand, Martin Busk, et al.
JACC. Cardiovascular Imaging|June 17, 2019
Application of Low Tube Potentials in CCTA: Results From the PROTECTION VI StudyThomas J Stocker, Jonathon Leipsic, Martin Hadamitzky, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 5, 2024
Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on ThrombosisBruna Gigante, Juan Tamargo, Stefan Agewall, et al.
JACC. Heart Failure|May 4, 2023
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEFErik Michaëlsson, Lars H Lund, Camilla Hage, et al.
Pageof 8